Prophylactic Ivermectin in COVID-19 Contacts

Zagazig University

Status and phase: Completed; Phase 3; Phase 2

Conditions: COVID

Treatments: Drug: Ivermectin Tablets

Study type: Interventional

Funder types: Other

Identifiers

NCT04422561

ZU-IRB#6150/31-5-2020

Details and patient eligibility

About

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

Enrollment: 340 patients

Sex: All

Ages: 16 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

family contact of confirmed COVID-19 case

Exclusion criteria

• refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

340 participants in 2 patient groups

Ivermectin group

Experimental group

Description:

Contacts who will receive prophylactic ivermectin

Treatment:

Drug: Ivermectin Tablets

Control group

No Intervention group

Description:

Contacts who will be only observed without prophylaxis